Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 9 Issue 2, June 2015

Volume 9 Issue 2

In this issue...

• A record year for deals

• Regenerative medicine on the up

• Academic-industrial partnerships prosper

• Antibody deals: an update

Cover image: Healthcare costs concept. Shawn Hempel / Getty Images

A record year for deals

    Feature

  • News Feature |

    Valuations and volume are up in a buoyant year for biopharmaceutical dealmaking. From tax inversions to gene therapy and, of course, immuno-oncology, 2014 and early 2015 featured plenty of wheeling and dealing.

    • Chris Morrison
  • Profiles

  • Advertisement Feature |

    Sanofi Pasteur, the vaccines division of Sanofi, is seeking partners with a common drive for excellence who will share the company’s pursuit of innovation.

    • Sanofi Pasteur
  • Advertisement Feature |

    HitGen’s advanced encoded library technology, including its recently released nonexclusive-use OpenDEL and macrocycle libraries, affords exciting opportunities for those involved in early-stage drug discovery around challenging targets.

  • Advertisement Feature |

    Already firmly established as one of the preeminent early-stage biomedical clusters and innovation communities in China, BioBAY is poised to become a leading force in diagnostics and related areas.

  • Advertisement Feature |

    For over 15 years, GENEWIZ has accelerated life science research and discovery by providing researchers with high-quality, cost-effective, time-saving and innovative genomics solutions.

  • Advertisement Feature |

    QIAGEN (Suzhou) Translational Medicine Co. (TMC) Ltd. is the first diagnostic R&D company focused on translational science in China. The company provides complete solutions for precision medicine through translational science.

  • Advertisement Feature |

    Point of care testing (POCT) enables rapid diagnostic tests to be performed while a patient is at a PoC facility, without the need for complex equipment or a wait of hours to days for reports from outside labs.

Antibody deals update

    Feature

  • News Feature |

    With the help of BioCentury, Biopharma Dealmakers is provides an update on the deal-trends analysis in the antibody field.

    • Biopharma Dealmakers
  • Profiles

  • Advertisement Feature |

    Invenra’s new proprietary platform, which combines cell-free protein expression with extreme miniaturization, enables the direct phenotypic interrogation of large numbers of full-length antibodies and their derivatives, empowering the discovery of next-generation biologics.

  • Advertisement Feature |

    Crescendo Biologics is poised to significantly impact the world of antibody therapeutics with the enormous potential of its Humabody technology and its product-discovery and engineering capabilities.

  • Advertisement Feature |

    Celonic is a private Swiss biotech company specializing in the production of recombinant proteins in mammalian cell systems for use in any stage of drug development.

  • Advertisement Feature |

    MicroVue Pan-Specific C3 Reagent Kit – A novel approach to fill the gap of animal-specific Complement ELISAs

  • Advertisement Feature |

    To all antibody hunters: “Have you screened enough?”

Academic-industrial partnerships prosper

    Feature

  • News Feature |

    Today, academic-industrial partnerships are part of an integrated development strategy for any of the world’s top ten pharmaceutical companies and a growing number of academic institutions.

    • Barbara Nasto
  • Profiles

  • Advertisement Feature |

    Close collaboration between A*STAR’s D3 (Drug Discovery and Development) unit and Experimental Therapeutics Centre accelerates the progress of research on drug candidates from the preclinical stage to proof-of-concept studies in humans.

  • Advertisement Feature |

    Three collaborative platforms—a Center for Innovation (COI), a tripartite industry-academia group (DUCR, TLO and UTEC) and the Translational Research Initiative (TRI)—showcase the University of Tokyo’s commitment to the development and commercialization of new healthcare technologies.

  • Advertisement Feature |

    The French Institute of Health and Medical Research (Inserm) has developed a unique model for technology transfer through Inserm Transfert, its subsidiary in charge of de-risking innovative preclinical projects and bridging discovery and clinical research.

  • Advertisement Feature |

    The Universidad Nacional Autónoma de México’s technology transfer office—Coordinación de Innovación y Desarrollo—provides a one-stop shop for innovation emerging from Mexico.

  • Advertisement Feature |

    With a distinguished history in the medical sciences and engineering, the University of Southampton continues to lead as a partner of choice in immunology and bioengineering.

Regenerative medicine

    Feature

  • News Feature |

    Regenerative medicine and advanced technologies make up a diverse group of therapeutics. As curative strategies for treating disease, they have the potential to alter the standard of care for many indications. With associated risks now tempered, investors and big pharma are showing interest.

    • Melanie Brazil
  • Profiles

  • Advertisement Feature |

    Regenerative medicine company International Stem Cell Corporation (ISCO) leads the way in developing new treatments for Parkinson’s disease and other clinical conditions using a unique stem cell approach.

  • Advertisement Feature |

    With its unique LentiVector platform and expanding state-of-the-art manufacturing facilities, Oxford BioMedica has established itself as the partner of choice for companies developing advanced therapy medicinal products.

  • Advertisement Feature |

    Eyevensys is pioneering mini-invasive electroporation to express therapeutic proteins in situ to treat major ophthalmic diseases.

  • Advertisement Feature |

    Cellect Biomed has developed a stem cell selection process it hopes will optimize clinical and research applications of stem cells and provide a boon to the stem cell industry. The company’s ultimate goal is to make stem cell transplantation a safer and more effective medical procedure.

  • Advertisement Feature |

    With promising early-phase data in hand, BrainStorm Cell Therapeutics is now putting its stem cell treatment for amyotrophic lateral sclerosis (ALS) through the rigors of phase 2 testing.

Search

Quick links